Tocilizumab in COVID-19: Enthusiasm vs. evidence

dc.date.accessioned2021-12-12T20:24:53Z
dc.date.available2021-12-12T20:24:53Z
dc.date.created2021-12-12T20:24:53Z
dc.date.issued2021
dc.identifierhttps://hdl.handle.net/20.500.12866/10191
dc.identifierhttps://doi.org/10.4103/lungindia.lungindia_766_20
dc.description.abstractBased on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series of 18 patients with severe COVID-19 treated with TCZ at our hospital. Our results coincide with the fact that the routine use of TCZ in severe COVID-19 is not robustly supported. We believe that the efficacy and safety of this drug and other related molecules should be validated in large randomized clinical trials
dc.languageeng
dc.publisherWolters Kluwer Health
dc.relationLung India
dc.relation0974-598X
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectadult
dc.subjectArticle
dc.subjectC reactive protein
dc.subjectclinical article
dc.subjectclinical decision making
dc.subjectclinical feature
dc.subjectclinical trial
dc.subjectcoronavirus disease 2019
dc.subjectCOVID-19
dc.subjectdisease severity
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectevidence based practice
dc.subjectfemale
dc.subjecthigh flow nasal cannula therapy
dc.subjecthuman
dc.subjectlife threat
dc.subjectlung embolism
dc.subjectmale
dc.subjectmiddle aged
dc.subjectmortality rate
dc.subjectoutcome assessment
dc.subjectpneumopericardium
dc.subjectrandomized controlled trial (topic)
dc.subjectsingle drug dose
dc.subjecttocilizumab
dc.subjecttreatment
dc.titleTocilizumab in COVID-19: Enthusiasm vs. evidence
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución